A detailed history of Victory Capital Management Inc transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 76,539 shares of RLAY stock, worth $496,738. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,539
Previous 68,859 11.15%
Holding current value
$496,738
Previous $571,000 12.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$5.9 - $8.02 $45,312 - $61,593
7,680 Added 11.15%
76,539 $499,000
Q1 2024

May 03, 2024

BUY
$7.5 - $12.07 $430,440 - $692,721
57,392 Added 500.5%
68,859 $571,000
Q4 2023

Feb 05, 2024

BUY
$6.01 - $11.48 $68,916 - $131,641
11,467 New
11,467 $126,000
Q4 2022

Feb 10, 2023

SELL
$14.16 - $24.02 $134,760 - $228,598
-9,517 Reduced 17.28%
45,560 $680,000
Q4 2022

Feb 09, 2023

SELL
$14.16 - $24.02 $170,670 - $289,513
-12,053 Reduced 17.95%
55,077 $822,000
Q3 2022

Nov 02, 2022

SELL
$18.07 - $31.37 $29,996 - $52,074
-1,660 Reduced 2.41%
67,130 $1.5 Million
Q2 2022

Aug 01, 2022

BUY
$13.31 - $34.88 $793,276 - $2.08 Million
59,600 Added 648.53%
68,790 $1.15 Million
Q1 2022

May 04, 2022

SELL
$20.26 - $32.36 $11,264 - $17,992
-556 Reduced 5.7%
9,190 $219,000
Q4 2021

Feb 07, 2022

BUY
$26.0 - $37.03 $36,478 - $51,953
1,403 Added 16.82%
9,746 $299,000
Q3 2021

Nov 02, 2021

SELL
$29.75 - $37.99 $23,086 - $29,480
-776 Reduced 8.51%
8,343 $263,000
Q2 2021

Aug 03, 2021

BUY
$27.5 - $38.19 $53,762 - $74,661
1,955 Added 27.29%
9,119 $334,000
Q1 2021

May 04, 2021

SELL
$32.52 - $61.53 $28,552 - $54,023
-878 Reduced 10.92%
7,164 $248,000
Q4 2020

Feb 01, 2021

BUY
$35.51 - $54.03 $285,571 - $434,509
8,042 New
8,042 $334,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $780M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.